Neil Desai

Dr. Neil Desai

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Cancer
Verified
Journal Article
Open access
PDF file
NDNeil Desai
Neil Desai
SSSasinya N. Scott
Sasinya N. Scott
EZEmily C. Zabor
Emily C. Zabor
ECEugene K. Cha
Eugene K. Cha
JHJoseph Hreiki
Joseph Hreiki
GIGopa Iyer
Gopa Iyer
BACKGROUND: The authors characterized the genetic landscape of chemoradiation‐treated urothelial carcinoma of the bladder (UCB) with the objective of identifying potential correlates of response.METHODS: Primary tumors with (n = 8) or without (n = 40) matched recurrent tumors from 48 patients who had non‐metastatic, high‐grade UCB and received treatment primarily with chemoradiation were analyzed using a next‐generation sequencing assay enriched for cancer‐related and canonical DNA damage response (DDR) genes. Protein expression of meiotic recombination 11 homolog (MRE11), a previously suggested biomarker, was assessed in 44 patients. Recurrent tumors were compared with primary tumors, and the clinical impact of likely deleterious DDR gene alterations was evaluated.RESULTS: The profile of alterations approximated that of prior UCB cohorts. Within 5 pairs of matched primary‐recurrent tumors, a median of 92% of somatic mutations were shared. A median 33% of mutations were shared between 3 matched bladder‐metastasis pairs. Of 26 patients (54%) who had DDR gene alterations, 12 (25%) harbored likely deleterious alterations. In multivariable analysis, these patients displayed a trend toward reduced bladder recurrence (hazard ratio, 0.32; P = .070) or any recurrence (hazard ratio, 0.37; P = .070). The most common of these alterations, ERCC2 (excision repair cross‐complementation group 2) mutations, were associated with significantly lower 2‐year metastatic recurrence (0% vs 43%; log‐rank P = .044). No impact of MRE11 protein expression on outcome was detected.CONCLUSIONS: A similar mutation profile between primary and recurrent tumors suggests that pre‐existing, resistant clonal populations represent the primary mechanism of chemoradiation treatment failure. Deleterious DDR genetic alterations, particularly recurrent alterations in ERCC2, may be associated with improved chemoradiation outcomes in patients with UCB. A small sample size necessitates independent validation of these observations. Cancer 2016;122:3715‐23. © 2016 American Cancer Society.

1 July 2021 in Advances in Radiation Oncology
Verified
Journal Article
Open access
MMMark F. McLaughlin
Mark F. McLaughlin
MFMichael R. Folkert
Michael R. Folkert
RTRobert D. Timmerman
Robert D. Timmerman
RHRaquibul Hannan
Raquibul Hannan
AGAurelie Garant
Aurelie Garant
NDNeil Desai
Neil Desai
The risk of rectal toxicity during and after prostate cancer radiation therapy is common to all treatment regimens. Hydrogel rectal spacers are increasingly being used to mitigate this risk and to facilitate dose-escalation, but also may infiltrate the rectal wall, with unclear clinical implication. We present a case of significant infiltration associated with severe late rectal injury (grade 4) and further grade 3 to 4 sequelae (recto-urethral fistula and associated osteomyelitis requiring exenteration) after high-dose stereotactic body radiation therapy for localized prostate cancer. The injury's temporal pattern associated with the expected timing of gel dissolution and displacement of infiltrated rectal layers potentially toward high dose regions together suggest a contributing role of the infiltration to the injury. In light of the rapid increase of hydrogel rectal spacer utilization, we review the case's evolution, concerning imaging findings, and associated literature and make suggestions regarding treatment planning and endoscopic assessment in the setting of infiltration or expected injury.

20 June 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JWJarey H. Wang
Jarey H. Wang
ASAlexander Sherry
Alexander Sherry
SBSoha Bazyar
Soha Bazyar
PSPhilip Anthony Sutera
Philip Anthony Sutera
NRNoura Radwan
Noura Radwan
AKAna P. Kiess
Ana P. Kiess
PURPOSE: Randomized clinical trials (RCTs) have shown progression-free survival (PFS) benefits of metastasis-directed therapy (MDT) without androgen deprivation therapy for oligometastatic castration-sensitive prostate cancer (omCSPC). Most patients with bone metastatic (BM) omCSPC recur with additional bone disease after MDT. We hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target subclinical bone disease and delay progression. METHODS: This is an investigator-initiated, multicenter, open-label phase II RCT. Eligible men with recurrent omCSPC with ≥one bone metastasis (≤three on conventional imaging and/or ≤five on molecular imaging) were randomly assigned (1:1) to stereotactic ablative radiation (SABR) MDT alone or SABR MDT with Ra223 (six cycles). Primary end point was composite PFS. RESULTS: From August 9, 2019, to March 2, 2023, 64 patients were randomly assigned, 33 to SABR MDT and 31 to SABR MDT/Ra223 balancing for key covariates. Most SABR MDT/Ra223 patients (87%) received six cycles of Ra223. The median PFS was 11.8 months with SABR MDT and 10.5 months with SABR MDT/Ra223 (adjusted hazard ratio [aHR], 1.42 [95% CI, 0.79 to 2.56]; P = .24). Seven patients (11%) experienced grade 3 treatment-related adverse events (no grade 4 or 5), 2 of 33 (6%) with SABR and 5 of 30 (17%) with SABR MDT/Ra223. Patients with high-risk (HiRi) pathogenic mutations in ATM , BRCA1/2 , RB1 , or TP53 had worse PFS (HR, 5.95 [95% CI, 1.83 to 19.3]; P = .003). Greater T-cell receptor (TCR) unique productive rearrangements were prognostic for improved PFS independent of the treatment arm (aHR, 0.45 [95% CI, 0.21 to 0.96]; P = .04). CONCLUSION: Adding Ra223 to SABR MDT in BM omCSPC does not delay progression of disease. We provide evidence for an HiRi mutational signature and TCR repertoire as prognostic biomarkers in omCSPC treated with SABR MDT, highlighting the importance of collecting biological correlates in RCTs for omCSPC.

25 January 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
NDNeil Desai
Neil Desai
ALAaron M Laine
Aaron M Laine
RTRobert Timmerman
Robert Timmerman
The metastatic state of most solid cancers traditionally has been regarded as an incurable dissemination of disease, with treatment focused on delaying progression rather than eliminating all tumour burden. In this setting, local therapies including surgery and radiotherapy are directed at quality of life end points and not at improvement in survival. However, improvements in imaging and systemic therapy have highlighted populations of patients with lower burden of metastatic disease, termed “oligometastatic,” who may present an exception. This condition is hypothesized to bridge the gap between incurable metastatic disease and locoregional disease, where miliary spread either has not occurred or remains eradicable. Consequently, elimination of such low-burden residual disease may “cure” some patients or delay further progression. Accordingly, use of local therapies with the intent of improving survival in oligometastatic disease has increased. Technological advances in radiation delivery with stereotactic ablative body radiotherapy (SAbR) in particular have provided a non-invasive and low-morbidity option. While observational studies have provided interesting preliminary data, significant work remains necessary to prove the merits of this treatment paradigm. This review discusses the data for the oligometastatic state and its treatment with SAbR, as well as challenges to its investigation.

5 June 2017 in BJU International
Verified
Journal Article
Open access
PDF file
VTVasu Tumati
Vasu Tumati
WJWilliam C. Jackson
William C. Jackson
AAAhmed E. Abugharib
Ahmed E. Abugharib
GRGanesh Raj
Ganesh Raj
CRClaus Roehrborn
Claus Roehrborn
NDNeil Desai
Neil Desai
Objectives: To describe the natural history of prostate cancer in men who experience a second biochemical recurrence ( BCR ) after salvage radiotherapy ( SRT ) after prostatectomy. Patients and Methods: After undergoing SRT at one of two institutions between 1986 and 2013, 286 patients experienced a second BCR , defined as two rises in prostate‐specific antigen ( PSA ) of ≥0.2 ng/mL above nadir. Event rates for distant metastasis ( DM ) or freedom from DM ( FFDM ), castration‐resistant prostate cancer ( CRPC ), prostate cancer‐specific survival ( PCSS ), and overall survival ( OS ) were estimated using the Kaplan–Meier method. Cox regression was used for comparative analyses. Results: At a median of 6.1 years after second BCR , DM , CRPC , PCSS and OS rates were 41%, 27%, 83% and 73%, respectively. On multivariable analysis, interval to second BCR <1 year (hazard ratio [ HR ] 2.66, 95% confidence interval [ CI ] 1.71–4.14; P < 0.001], Gleason score 8–10 ( HR 1.65, 95% CI 1.07–2.54; P = 0.022), and concurrent ADT during SRT ( HR 1.76, 95% CI 1.08–2.88; P = 0.024) were associated with FFDM , while PCSS was associated with interval to second BCR <1 year ( HR 3.00, 95% CI 1.69–5.32; P < 0.001) and concurrent ADT during SRT ( HR 2.15, CI 1.13–4.08; P = 0.019). These risk factors were used to stratify patients into three groups, with 6‐year FFDM rates of 71%, 59% and 33%, and PCSS rates of 89%, 79%, and 65%, respectively. Conclusion: Following second BCR after SRT , clinical progression is enriched in a subgroup of patients with prostate cancer, while others remain without DM for long intervals. Stratifying patients into risk groups using prognostic factors may aid counselling and future trial design.

12 April 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
PRPer Munck Af Rosenschold
Per Munck Af Rosenschold
MZMichael J. Zelefsky
Michael J. Zelefsky
AAAditya P. Apte
Aditya P. Apte
AJAndrew Jackson
Andrew Jackson
Jung Hun OhJung Hun Oh
Jung Hun Oh
JDJoseph O. Deasy
Joseph O. Deasy
To determine if reduced dose delivery uncertainty is associated with daily image-guidance (IG) and Prostate Specific Antigen Relapse Free Survival (PRFS) in intensity-modulated radiotherapy (IMRT) of high-risk prostate cancer (PCa). Planning data for consecutive PCa patients treated with IMRT (n = 67) and IG-IMRT (n = 35) was retrieved. Using computer simulations of setup errors, we estimated the patient-specific uncertainty in accumulated treatment dose distributions for the prostate and for posterolateral aspects of the gland that are at highest risk for extra-capsular disease. Multivariate Cox regression for PRFS considering Gleason score, T-stage, pre-treatment PSA, number of elevated clinical risk factors (T2c+, GS7+ and PSA10+), nomogram-predicted risk of extra-capsular disease (ECD), and dose metrics was performed. For IMRT vs. IG-IMRT, plan dosimetry values were similar, but simulations revealed uncertainty in delivered dose external to the prostate was significantly different, due to positioning uncertainties. A patient-specific interaction term of the risk of ECD and risk of low dose to the ECD (p = 0.005), and the number of elevated clinical risk factors (p = 0.008), correlate with reduced PRFS. Improvements in PSA outcomes for high-risk PCa using IG-IMRT vs. IMRT without IG may be due to improved dosimetry for ECD.